Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Brockstein

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II study of sorafenib in patients with metastatic or recurrent sarcomasRobert G Maki, David R D'Adamo, Mary L Keohan, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2019
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L Jones, Mark J Ratain, Peter J O'Dwyer, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II study of sorafenib in patients with metastatic or recurrent sarcomasRobert G Maki, David R D'Adamo, Mary L Keohan, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2019
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L Jones, Mark J Ratain, Peter J O'Dwyer, et al.
Pageof 4